UNSPSC 51411602: Bamethan

This classification denotes a beta-adrenergic agonist with the molecular formula C12H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y08ZFJ9TFK, chemically known as benzyl alcohol, alpha-((butylamino)methyl)-p-hydroxy- but generally known as bamethan, which bears US NIH Compound Identifier 2292. Bamethan most often comes in base and sulfate forms. European Medicines Agency schedules Bamethan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06096MIG.

UNSPSC 51411602 Bamethan, a Commodity code, covers pharmaceutical products supplied to state and local health agencies, emergency services, and medicaid programs. State and local governments procure under this code primarily for emergency medical services, institutional healthcare facilities, and pharmacy benefit programs serving public employees and beneficiaries. The issuing bodies include municipal fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across member jurisdictions. Work being solicited ranges from direct supply of individual medication units to manufacturers and wholesalers to broader pharmacy benefit program management and direct-to-manufacturer contracting arrangements that bypass traditional pharmacy benefit managers.

Recent activity spans Florida, Minnesota, and Texas. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) posted April 24, 2026 with a due date of April 8, 2026 for Advanced Life Support Medications—specifically Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials for use by Tampa Fire Rescue—with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) posted January 20, 2026 with a March 26, 2026 due date for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities including Oregon, requiring compliance with cGMP and DSCSA standards and relationships with authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora) and Cardinal Health. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, gathering market intelligence on direct contracting models outside traditional pharmacy benefit manager and group purchasing organization arrangements.